Primary Series and Booster Coronavirus Disease 2019 Vaccine Effectiveness in a Cohort of Healthcare Workers in Albania During a BA.1 and BA.2 Variant Period, January-May 2022.
COVID-19
Omicron
booster dose
healthcare workers
vaccine effectiveness
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
25
05
2023
accepted:
19
09
2023
medline:
27
10
2023
pubmed:
27
10
2023
entrez:
27
10
2023
Statut:
epublish
Résumé
Healthcare workers (HCWs) have experienced high rates of coronavirus disease 2019 (COVID-19) morbidity and mortality. We estimated COVID-19 2-dose primary series and monovalent booster vaccine effectiveness (VE) against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (BA.1 and BA.2) infection among HCWs in 3 Albanian hospitals during January-May 2022. Study participants completed weekly symptom questionnaires, underwent polymerase chain reaction (PCR) testing when symptomatic, and provided quarterly blood samples for serology. We estimated VE using Cox regression models (1 - hazard ratio), with vaccination status as the time-varying exposure and unvaccinated HCWs as the reference group, adjusting for potential confounders: age, sex, prior SARS-CoV-2 infection (detected by PCR, rapid antigen test, or serology), and household size. At the start of the analysis period, 76% of 1462 HCWs had received a primary series, 10% had received a booster dose, and 9% were unvaccinated; 1307 (89%) HCWs had evidence of prior infection. Overall, 86% of primary series and 98% of booster doses received were BNT162b2. The median time interval from the second dose and the booster dose to the start of the analysis period was 289 (interquartile range [IQR], 210-292) days and 30 (IQR, 22-46) days, respectively. VE against symptomatic PCR-confirmed infection was 34% (95% confidence interval [CI], -36% to 68%) for the primary series and 88% (95% CI, 39%-98%) for the booster. Among Albanian HCWs, most of whom had been previously infected, COVID-19 booster dose offered improved VE during a period of Omicron BA.1 and BA.2 circulation. Our findings support promoting booster dose uptake among Albanian HCWs, which, as of January 2023, was only 20%.
Sections du résumé
Background
UNASSIGNED
Healthcare workers (HCWs) have experienced high rates of coronavirus disease 2019 (COVID-19) morbidity and mortality. We estimated COVID-19 2-dose primary series and monovalent booster vaccine effectiveness (VE) against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (BA.1 and BA.2) infection among HCWs in 3 Albanian hospitals during January-May 2022.
Methods
UNASSIGNED
Study participants completed weekly symptom questionnaires, underwent polymerase chain reaction (PCR) testing when symptomatic, and provided quarterly blood samples for serology. We estimated VE using Cox regression models (1 - hazard ratio), with vaccination status as the time-varying exposure and unvaccinated HCWs as the reference group, adjusting for potential confounders: age, sex, prior SARS-CoV-2 infection (detected by PCR, rapid antigen test, or serology), and household size.
Results
UNASSIGNED
At the start of the analysis period, 76% of 1462 HCWs had received a primary series, 10% had received a booster dose, and 9% were unvaccinated; 1307 (89%) HCWs had evidence of prior infection. Overall, 86% of primary series and 98% of booster doses received were BNT162b2. The median time interval from the second dose and the booster dose to the start of the analysis period was 289 (interquartile range [IQR], 210-292) days and 30 (IQR, 22-46) days, respectively. VE against symptomatic PCR-confirmed infection was 34% (95% confidence interval [CI], -36% to 68%) for the primary series and 88% (95% CI, 39%-98%) for the booster.
Conclusions
UNASSIGNED
Among Albanian HCWs, most of whom had been previously infected, COVID-19 booster dose offered improved VE during a period of Omicron BA.1 and BA.2 circulation. Our findings support promoting booster dose uptake among Albanian HCWs, which, as of January 2023, was only 20%.
Identifiants
pubmed: 37885795
doi: 10.1093/ofid/ofad479
pii: ofad479
pmc: PMC10599317
doi:
Banques de données
ClinicalTrials.gov
['NCT04811391']
Types de publication
Journal Article
Langues
eng
Pagination
ofad479Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. All authors: No reported conflicts.
Références
Lancet Reg Health Eur. 2023 Apr;27:100584
pubmed: 37013112
IJID Reg. 2023 Sep;8:19-27
pubmed: 37317681
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
Clin Infect Dis. 2022 Dec 19;75(12):2161-2168
pubmed: 35511586
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
BMJ Open. 2022 Mar 23;12(3):e057741
pubmed: 35321895
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
EClinicalMedicine. 2022 Jan;43:101253
pubmed: 34977517
BMJ Open. 2021 Oct 28;11(10):e055085
pubmed: 34711602
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Nat Commun. 2022 Jun 2;13(1):3082
pubmed: 35654888
Lancet Infect Dis. 2022 Jul;22(7):931-933
pubmed: 35623379
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
Lancet Infect Dis. 2023 May;23(5):556-567
pubmed: 36681084
Respirology. 2022 Jun;27(6):411-426
pubmed: 35048469
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Rev Med Virol. 2022 Jul;32(4):e2358
pubmed: 35445774
Lancet Infect Dis. 2022 Aug;22(8):1114-1116
pubmed: 35752196